ST-01156

· SEED Therapeutics, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for ST-01156, covering 2026-02-18 to 2026-02-18. Get the full timeline:

Most recent: Clinical Trial Update: A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies [Phase 1]

See pricing